Lifeworks Advisors LLC Invests $294,000 in Axon Enterprise, Inc (NASDAQ:AXON)

Lifeworks Advisors LLC purchased a new stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 558 shares of the biotechnology company's stock, valued at approximately $294,000.

Other institutional investors have also made changes to their positions in the company. Fourth Dimension Wealth LLC acquired a new position in Axon Enterprise during the fourth quarter worth about $30,000. Bartlett & CO. Wealth Management LLC raised its stake in Axon Enterprise by 132.0% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 33 shares in the last quarter. Catalyst Capital Advisors LLC acquired a new position in shares of Axon Enterprise during the first quarter worth $32,000. Alpine Bank Wealth Management acquired a new position in shares of Axon Enterprise during the first quarter worth $40,000. Finally, Elequin Capital LP acquired a new position in shares of Axon Enterprise during the fourth quarter worth $46,000. 79.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

AXON has been the subject of several research analyst reports. UBS Group initiated coverage on shares of Axon Enterprise in a report on Wednesday, July 16th. They set a "neutral" rating and a $820.00 price target for the company. Needham & Company LLC upped their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Morgan Stanley set a $885.00 price target on shares of Axon Enterprise and gave the stock an "overweight" rating in a report on Friday, July 11th. Bank of America upped their price target on shares of Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a report on Wednesday, June 4th. Finally, JMP Securities upped their price target on shares of Axon Enterprise from $725.00 to $825.00 and gave the stock a "market outperform" rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $772.08.

Axon Enterprise Trading Up 3.6%

AXON stock traded up $25.75 during trading on Friday, hitting $735.01. The company had a trading volume of 654,601 shares, compared to its average volume of 627,317. The business has a 50-day moving average of $763.82 and a 200-day moving average of $650.42. Axon Enterprise, Inc has a one year low of $279.02 and a one year high of $830.21. The stock has a market cap of $57.22 billion, a PE ratio of 177.54, a PEG ratio of 79.06 and a beta of 1.29. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The firm had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same period last year, the business posted $1.15 EPS. The business's revenue was up 31.3% compared to the same quarter last year. Research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Activity

In other Axon Enterprise news, Director Michael Garnreiter sold 5,913 shares of the stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the completion of the sale, the director directly owned 17,740 shares in the company, valued at approximately $13,482,400. This trade represents a 25.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Jennifer H. Mak sold 75 shares of the stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $771.81, for a total value of $57,885.75. Following the sale, the chief accounting officer owned 15,240 shares of the company's stock, valued at approximately $11,762,384.40. The trade was a 0.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,642 shares of company stock worth $25,090,528. 4.40% of the stock is owned by insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.